Detection of autoreactive CD4+ T cells by MHC class II multimers in HLA-linked human autoimmune diseases.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
03 05 2021
Historique:
entrez: 3 5 2021
pubmed: 4 5 2021
medline: 22 9 2021
Statut: ppublish

Résumé

Recognition of self-peptides in association with distinct HLA class II alleles by autoreactive CD4+ T cells is central for loss of immunological tolerance leading to autoimmune disease. However, identifying immunodominant self-peptides and characterizing autoreactive T cells is challenging. In this issue of the JCI, Falta et al. identify a disease-associated complementarity-determining region 3β motif specific for beryllium-modified C-C motif ligand 4 (CCL4) and CCL3 self-peptides in patients with chronic beryllium disease (CBD), a granulomatous lung disorder with a known HLA class II allelic association. Detection of these antigen-specific CD4+ T cells by beryllium-pulsed HLA-DP2 tetramers presenting CCL4/CCL3 confirms these autoantigens in humans and mice and enables monitoring in the progress of disease. Detection of autoreactive CD4+ T cells by peptide-MHC class II multimers allows for the detailed characterization of disease-promoting T cells. This knowledge has profound implications for the monitoring and development of targeted therapies in human autoimmune disorders.

Identifiants

pubmed: 33938450
pii: 148674
doi: 10.1172/JCI148674
pmc: PMC8087195
doi:
pii:

Substances chimiques

Autoantigens 0
Beryllium OW5102UV6N

Types de publication

Journal Article Research Support, Non-U.S. Gov't Comment

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentOn

Références

J Invest Dermatol. 2008 Dec;128(12):2850-8
pubmed: 18563178
J Immunol. 2018 Dec 15;201(12):3524-3533
pubmed: 30455401
J Autoimmun. 2018 Aug;92:47-56
pubmed: 29853344
Nat Commun. 2016 Aug 30;7:12614
pubmed: 27571776
J Immunol. 2006 Sep 15;177(6):3874-83
pubmed: 16951350
Clin Immunol. 2007 Mar;122(3):330-7
pubmed: 17113829
Thyroid. 2021 Feb 8;:
pubmed: 33208049
J Clin Invest. 2006 May;116(5):1159-66
pubmed: 16670756
J Immunol. 2011 Jul 15;187(2):1039-46
pubmed: 21653833
J Autoimmun. 2020 Jan;106:102306
pubmed: 31383567
Front Immunol. 2020 Mar 18;11:474
pubmed: 32256501
Nat Med. 2019 May;25(5):734-737
pubmed: 30911136
J Clin Invest. 2021 May 3;131(9):
pubmed: 33630763
J Invest Dermatol. 1998 Jan;110(1):62-6
pubmed: 9424089
J Exp Med. 2013 Jul 1;210(7):1403-18
pubmed: 23797096
BMC Bioinformatics. 2006 Dec 18;7 Suppl 5:S7
pubmed: 17254312
Arthritis Rheumatol. 2019 Apr;71(4):518-528
pubmed: 30390384
J Immunol. 2014 Nov 1;193(9):4391-9
pubmed: 25252957
Arthritis Rheumatol. 2020 Apr;72(4):565-575
pubmed: 31682074

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH